Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study
- DOI
- 10.1007/s13555-026-01729-7
- Published
- 2026-03-31
- Container
- Dermatology and Therapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01729-7,
title = {Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study},
author = {Igor Snast and Yuliya Valdman-Grinshpoun and Naji Bathish and Hagit Matz and Yuri Shclar and Sari Murad and Tali Czarnowicki and Eran Shavit and Liuqing Yang and Sandra Goss and Inbal Piller Maor and Assaf Halperin and Shiran Naftalberg Blonder and Raanan Cohen and Alex Bleterman and Moran Barak and Lev Pavlovsky},
year = {2026},
journal = {Dermatology and Therapy},
doi = {10.1007/s13555-026-01729-7},
url = {https://doi.org/10.1007/s13555-026-01729-7}
}RIS
TY - JOUR TI - Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study AU - Igor Snast AU - Yuliya Valdman-Grinshpoun AU - Naji Bathish AU - Hagit Matz AU - Yuri Shclar AU - Sari Murad AU - Tali Czarnowicki AU - Eran Shavit AU - Liuqing Yang AU - Sandra Goss AU - Inbal Piller Maor AU - Assaf Halperin AU - Shiran Naftalberg Blonder AU - Raanan Cohen AU - Alex Bleterman AU - Moran Barak AU - Lev Pavlovsky PY - 2026 JO - Dermatology and Therapy DO - 10.1007/s13555-026-01729-7 UR - https://doi.org/10.1007/s13555-026-01729-7 ER -
APA
Snast, I., Valdman-Grinshpoun, Y., Bathish, N., Matz, H., Shclar, Y., Murad, S., Czarnowicki, T., Shavit, E., Yang, L., Goss, S., Maor, I. P., Halperin, A., Blonder, S. N., Cohen, R., Bleterman, A., Barak, M., & Pavlovsky, L. (2026). Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01729-7
Source records
- crossref · retrieved 2026-09-25T07:26:59.608Z